Hillsdale Investment Management’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-97,400
Closed -$4.28M 637
2024
Q1
$4.28M Buy
97,400
+7,680
+9% +$339K 0.34% 101
2023
Q4
$4.26M Sell
89,720
-290
-0.3% -$12.2K 0.35% 95
2023
Q3
$3.99M Sell
90,010
-6,090
-6% -$283K 0.37% 93
2023
Q2
$4.59M Sell
96,100
-13,000
-12% -$586K 0.42% 73
2023
Q1
$4.29M Buy
109,100
+600
+0.6% +$21.8K 0.37% 100
2022
Q4
$3.07M Sell
108,500
-12,800
-11% -$366K 0.26% 137
2022
Q3
$3.65M Hold
121,300
0.33% 120
2022
Q2
$4.12M Sell
121,300
-200
-0.2% -$7.17K 0.33% 112
2022
Q1
$5.45M Hold
121,500
0.35% 92
2021
Q4
$5.61M Buy
121,500
+57,100
+89% +$2.3M 0.38% 83
2021
Q3
$2.16M Buy
+64,400
New +$2.19M 0.17% 154
2018
Q4
Sell
-700
Closed -$26K 614
2018
Q3
$26K Sell
700
-200
-22% -$5.4K ﹤0.01% 314
2018
Q2
$19K Buy
+900
New +$15.9K ﹤0.01% 333

Other funds holding IRMD

Hillsdale Investment Management's IRMD Position: Q2 2024 in Review

Hillsdale Investment Management sold out of iRadimed (IRMD) in Q2 2024, closing a stake of 97,400 shares — an estimated $4.28M sold.

Hillsdale Investment Management first reported a position in IRMD in Q2 2018 and held it in 13 quarters. The position peaked at $5.61M in Q4 2021. 139 funds tracked by Wall St. Rank hold IRMD as of Q2 2024.

  • Hillsdale Investment Management reported no remaining iRadimed position as of Q2 2024 after selling out during the quarter.
  • Hillsdale Investment Management sold 97,400 iRadimed shares in Q2 2024, an estimated $4.28M.
  • Hillsdale Investment Management first reported a position in iRadimed in Q2 2018 and held it in 13 quarters.
  • Hillsdale Investment Management's iRadimed position peaked at $5.61M in Q4 2021.
  • 139 funds tracked by Wall St. Rank held iRadimed as of Q2 2024.

Based on Hillsdale Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.